Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : INCY crawled time : 14:00 save search
Incyte to Present at Upcoming March 2024 Investor Conference
Published: 2024-02-15 (Crawled : 14:00) - biospace.com/
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: 0.35%
H: 3.06%
C: 1.51%
conference
Agilent Announces Collaboration with Incyte to Develop Advanced Companion Diagnostics in Hematology and Oncology
Published: 2024-01-30 (Crawled : 14:00) - biospace.com/
A | $140.22 -0.36% 0.0% 1.5M
|
Health Technology
|
| O: 0.0%
H: 1.27%
C: 1.09%
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: 0.05%
H: 0.0%
C: -2.02%
collaboration companion diagnostics advanced
Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
Published: 2024-01-23 (Crawled : 14:00) - biospace.com/
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: 0.37%
H: 0.75%
C: 0.23%
report financial results
Incyte to Present at Upcoming Investor Conferences - December 15, 2022
Published: 2022-12-15 (Crawled : 14:00) - biospace.com/
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: -0.83%
H: 0.66%
C: 0.3%
Incyte to Present at Upcoming Investor Conferences - November 17, 2022
Published: 2022-11-17 (Crawled : 14:00) - biospace.com/
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: -0.17%
H: 2.14%
C: 1.8%
Recludix Pharma Announces the Appointment of Accomplished Immunologist and Pharmacologist Paul A. Smith, Ph.D., as Senior Vice President of Biology
Published: 2022-10-20 (Crawled : 14:00) - biospace.com/
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: 0.14%
H: 1.08%
C: -1.05%
pharma
Vitiligo Treatment Market Size Worth US$ 2.42 Billion With CAGR of 6.14% from 2022 to 2030 | Exclusive Report by Growth Plus Reports
Published: 2022-09-05 (Crawled : 14:00) - prnewswire.com
GLAXF | $20.2 0.65% -14.18% 510
|
Health Technology
| Email alert
Add to watchlist
ALPMF | $9.48 -8.41% 43.47% 22
|
Health Technology
| Email alert
Add to watchlist
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
| Email alert
Add to watchlist
ALPMY | $9.2715 -2.92% -1.11% 500K
|
Manufacturing
| Email alert
Add to watchlist
GSK | $40.5 -0.39% -1.09% 2.7M
|
Health Technology
| Email alert
Add to watchlist
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
| Email alert
Add to watchlist
ABBV | $161.67 -0.38% -0.19% 3.4M
|
Health Technology
| Email alert
Add to watchlist
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
| Email alert
Add to watchlist
treatment report plus growth market
Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
Published: 2022-03-25 (Crawled : 14:00) - biospace.com/
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: 0.33%
H: 0.29%
C: 0.01%
jakavi treatment disease positive chmp
Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis
Published: 2022-01-28 (Crawled : 14:00) - biospace.com/
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 0.33%
H: 3.25%
C: 3.2%
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: -0.2%
H: 3.93%
C: 3.89%
olumiant fda atopic dermatitis program dermatitis baricitinib phase 3 lupus
Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT®
Published: 2021-12-24 (Crawled : 14:00) - biospace.com/
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
| Email alert
Add to watchlist
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
| Email alert
Add to watchlist
tyvyt new drug application drug china
FDA Action Alert: Incyte, Verrica and Ascendis
Published: 2021-09-20 (Crawled : 14:00) - biospace.com/
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: 3.9%
H: 1.92%
C: -2.68%
fda
Nimble Therapeutics and Incyte Expand their Strategic Research Collaboration to Discover Additional Novel Peptide Therapeutics
Published: 2021-09-14 (Crawled : 14:00) - biospace.com/
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: 0.7%
H: 0.1%
C: -0.99%
collaboration research therapeutics
Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis
Published: 2021-07-16 (Crawled : 14:00) - prnewswire.com
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: 0.3%
H: 0.44%
C: -2.37%
new drug baricitinib treatment dermatitis drug atopic dermatitis
Gainers vs Losers
| 45% | 55% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.74 79.7% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 5.5M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4004 45.07% 31.75% 130M
|
Electronic Technology
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
OMQS | $0.7038 35.35% 24.3% 3.5M
|
Professional, Scientific, and T...
SNPO | $10.54 29.48% 22.88% 3.9M
|
SNGX | $0.47 21.73% 17.38% 130M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.